NasdaqGS:SVRA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Savara Inc. operates as an orphan lung disease company.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Savara's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SVRA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.8%

SVRA

-0.8%

US Biotechs

-0.7%

US Market


1 Year Return

-20.6%

SVRA

26.1%

US Biotechs

5.3%

US Market

Return vs Industry: SVRA underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: SVRA underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

SVRAIndustryMarket
7 Day-7.8%-0.8%-0.7%
30 Day-22.1%9.3%4.6%
90 Day-17.6%18.3%14.0%
1 Year-20.6%-20.6%27.4%26.1%7.6%5.3%
3 Year-65.6%-65.6%30.2%25.8%34.9%26.1%
5 Yearn/a-6.7%-12.0%62.3%44.7%

Price Volatility Vs. Market

How volatile is Savara's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Savara undervalued compared to its fair value and its price relative to the market?

1.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SVRA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SVRA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SVRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SVRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SVRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SVRA is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Savara forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

43.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SVRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SVRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SVRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SVRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SVRA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SVRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Savara performed over the past 5 years?

-40.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SVRA is currently unprofitable.

Growing Profit Margin: SVRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SVRA is unprofitable, and losses have increased over the past 5 years at a rate of -40.6% per year.

Accelerating Growth: Unable to compare SVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SVRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: SVRA has a negative Return on Equity (-93.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is Savara's financial position?


Financial Position Analysis

Short Term Liabilities: SVRA's short term assets ($107.4M) exceed its short term liabilities ($7.7M).

Long Term Liabilities: SVRA's short term assets ($107.4M) exceed its long term liabilities ($24.9M).


Debt to Equity History and Analysis

Debt Level: SVRA's debt to equity ratio (28.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if SVRA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SVRA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SVRA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 36.3% each year.


Next Steps

Dividend

What is Savara current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SVRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SVRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SVRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SVRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SVRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Rob Neville (54yo)

12.08yrs

Tenure

US$1,047,816

Compensation

Mr. Robert Neville, also known as Rob, Co-founded Savara Inc. in June 2008 and has been its Chief Executive Officer since June 2008. Mr. Neville has been the Executive Chairman of Savara, Inc. since June 2 ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD1.05M) is above average for companies of similar size in the US market ($USD612.38K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Neville
Co-Founder12.08yrsUS$1.05m0.95% $1.0m
David Lowrance
CFO & Secretary3.67yrsUS$699.03kno data
Jaakko Jouhikainen
Chief Business Officer0.083yrUS$1.01m0.32% $336.8k
Anne Erickson
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Kate McCabe
Vice President of Legal Affairs2.33yrsno datano data
John Lord
Senior VP and Head of Research & Developmentno datano datano data
Cecilia Ganslandt
Head of Clinical Development4yrsno datano data
Inge Tarnow
VP, Senior Directorno datano datano data
Mette Vinge
VP & Head of Regulatory Affairsno datano datano data
Mike Ciesla
Senior VP of Finance & Director of SEC Report1.5yrsno datano data
Pernille Hemmingsen
VP & Head of Pharmaceutical Development1.08yrsno datano data
Badrul Chowdhury
Chief Medical Officer0.67yrno datano data

1.9yrs

Average Tenure

54yo

Average Age

Experienced Management: SVRA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Robert Neville
Co-Founder12.08yrsUS$1.05m0.95% $1.0m
David Ramsay
Independent Director9.08yrsUS$71.93k0.23% $245.5k
Joseph S. McCracken
Lead Independent Director0.58yrUS$63.99k0.19% $199.7k
Richard Hawkins
Independent Director9.75yrsUS$61.93kno data
Nevan Elam
Independent Director11.42yrsUS$64.93k0.042% $43.6k
Michael Konstan
Member of Clinical Advisory Boardno datano datano data
Patrick Flume
Member of Clinical Advisory Boardno datano datano data
Matthew Pauls
Independent Director4.75yrsUS$63.85k0.0013% $1.3k
Felix Ratjen
Member of Clinical Advisory Boardno datano datano data
Elliott Dasenbrook
Member of Clinical Advisory Boardno datano datano data
Grant Waterer
Member of Clinical Advisory Boardno datano datano data
Francesco Bonella
Member of Clinical Advisory Boardno datano datano data

9.4yrs

Average Tenure

54.5yo

Average Age

Experienced Board: SVRA's board of directors are considered experienced (9.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.4%.


Top Shareholders

Company Information

Savara Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Savara Inc.
  • Ticker: SVRA
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$104.896m
  • Shares outstanding: 52.19m
  • Website: https://www.savarapharma.com

Number of Employees


Location

  • Savara Inc.
  • Building 3
  • Suite 200
  • Austin
  • Texas
  • 78746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SVRANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2017
YB4PDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2017

Biography

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:02
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.